Skip to content
10-Q

Quarterly Report

Summit Therapeutics Inc. SMMT

0001599298-26-000039

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 24, 2026 776.16M sh
Shares Diluted Q1 2026 · Mar 31, 2026 775.46M sh
Shares Diluted Q1 2026 · Mar 31, 2025 738.08M sh
Capex Q1 2026 · Mar 31, 2026 $245K
Capex Q1 2026 · Mar 31, 2025 $422K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$122.29M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$61.17M
Short Term Investments Q1 2026 · Mar 31, 2026 $492.22M
Short Term Investments Q1 2026 · Dec 31, 2025 $488.18M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $106.52M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $225.27M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $211.53M
Stockholders Equity Q1 2026 · Mar 31, 2026 $545.93M
Stockholders Equity Q1 2026 · Dec 31, 2025 $658.86M
Stockholders Equity Q1 2026 · Mar 31, 2025 $344.33M
Stockholders Equity Q1 2026 · Dec 31, 2024 $388.75M
Current Liabilities Q1 2026 · Mar 31, 2026 $83.27M
Current Liabilities Q1 2026 · Dec 31, 2025 $72.99M
Total Liabilities Q1 2026 · Mar 31, 2026 $101.92M
Total Liabilities Q1 2026 · Dec 31, 2025 $92.32M
Current Assets Q1 2026 · Mar 31, 2026 $616.6M
Current Assets Q1 2026 · Dec 31, 2025 $720.3M
Total Assets Q1 2026 · Mar 31, 2026 $647.86M
Total Assets Q1 2026 · Dec 31, 2025 $751.18M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.24
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.09
Eps Basic Q1 2026 · Mar 31, 2026 −$0.24
Eps Basic Q1 2026 · Mar 31, 2025 −$0.09
Sga Expense Q1 2026 · Mar 31, 2026 $62.59M
Sga Expense Q1 2026 · Mar 31, 2025 $15.59M
Rd Expense Q1 2026 · Mar 31, 2026 $132.62M
Rd Expense Q1 2026 · Mar 31, 2025 $51.27M
Net Income Q1 2026 · Mar 31, 2026 −$189.42M
Net Income Q1 2026 · Mar 31, 2025 −$62.91M